Oncologists affiliated to SCUK treat a wide range of cancer types and work closely with our teams. This ensures that our patients receive truly comprehensive cancer care at every stage.

Dr Rovel Colaco

Consultant Clinical Oncologist

Dr Colaco is a consultant clinical oncologist with a specialist interest in proton therapy,stereotactic radiotherapy and adult primary brain tumours. He also specialises in stereotactic radiotherapy for brain metastases and oligo-metastatic cancers.

After completing his training as a specialist registrar in Clinical Oncology at the Christie, Dr Colaco was selected as the first UK doctor to train in proton therapy spending 12 months working in proton therapy at the University of Florida Proton Therapy Institute in Jacksonville, Florida.

He was subsequently the first graduate of the Stereotactic Radiosurgery and Radiotherapy program at Yale University in Connecticut, USA, where he worked with a variety of radiotherapy delivery platforms including the Cyberknife, Gammaknife and Novalis TX treating patients with stereotactic radiosurgery(SRS) for brain metastases and stereotactic ablative radiotherapy (SABR) for both primary lung tumours and oligo-metastatic disease from other primary cancer sites.

Following his return from the United States, he was appointed as a consultant clinical oncologist at The Christie where he specialises in the treatment of adult brain tumours and paediatric tumours along with stereotactic radiotherapy for brain metastases and oligo-metastases.

He also sees patients for proton therapy and is involved in the development of The Christie proton beam centre and in the Christie program for oligo-metastatic disease including treating tumours which have metastasised to bone, spine and lymph nodes with SABR.

Research Interest
Proton therapy, stereotactic radiotherapy, CNS tumours – Dr Colaco has presented at international conferences and published several papers on the use of proton therapy and stereotactic radiotherapy for a variety of cancer sites. He is the principal investigator at the Christie for the CORE trial which is examining the role of stereotactic radiotherapy in oligo-metastatic breast, lung and prostate cancers.

Dr David Thomson

Consultant Clinical Oncologist

Dr Thomson is Consultant Clinical Oncologist at The Christie and Honorary Senior Lecturer at The University of Manchester, with a specialist interest in head and neck cancer.

Dr Thomson qualified from Oxford University Medical School in 2004. He was awarded the Greenhill Exhibition in Medicine (Trinity College, Oxford) and achieved a First Class honours degree in Physiological Sciences (2001). He completed core medical training in Oxford and Manchester in 2009. He was then appointed Academic Clinical Fellow/Specialty Registrar in Clinical Oncology in the North West of England (2009-2015).

During a two year Doctor of Medicine (MD) research degree at the University of Manchester (2013-2015), he gained excellent clinical and research experience in technical head and neck radiotherapy; and in proton beam therapy, with Fellowships in the United States (Massachusetts General Hospital, 2013; University of Pennsylvania, 2014). He also gained experience in stereotactic ablative radiotherapy for oligometastatic disease at Princess Alexandra Hospital, Brisbane (2015).

He is a member of the National Cancer Research Institute Clinical Sub-Group for Head and Neck Cancer, Research Lead for the Manchester Cancer Head and Neck Pathway Board and Deputy Chief Investigator for the UK phase III NIMRAD trial. He also has an interest in education and was awarded a Postgraduate Certificate in Medical Education with Distinction (Edge Hill University, 2015).

Dr David Woolf

Consultant Clinical Oncologist

Dr Woolf is a graduate of the University of Birmingham. Core medical and Clinical Oncology training was in London (University College Hospital, The Royal Free and St Bartholomews’). A Master’s Degree in Oncology at the Institute of Cancer Research and a Doctorate of Medicine after research at Mount Vernon Cancer Centre.

Dr Woolf has a particular interest in the development of high quality health care participating as a member of the Keogh Quality of Care Review Inspections Panel and as Clinical Expert in Care Quality Commission (CQC) inspections.

During his career Dr Woolf has had over 20 publications in peer reviewed journals and published book chapters as well as over 40 oral and poster presentations to national and international conferences. These include multiple publications and presentations in the field of breast and lung cancer.

Dr Woolf plans and delivers radiotherapy at The Christie to patients with breast and lung cancers and also gives Stereotactic Ablative Radiotherapy (SABR) for lung cancers and oligometastases (cancers that have spread to the lungs). In addition he gives hormone therapy (endocrine therapy), chemotherapy and targeted drugs.

Dr Woolf also runs regular teaching sessions for junior doctors. He examines on The Christie FRCR examination course and has worked extensively with the Royal College of Radiologists to enhance training for clinical oncologists.